Abstract:Damage and loss of retinal ganglion cells (RGCs) can cause visual impairment. The underlying molecular mechanisms that mediate RGC death in ischemic retinal diseases are still unclear. In this study, we sought to understand the neuroprotective effect of rapamycin, the selective inhibitor of mTORC1, on RGC survival and the cellular mechanics that mediate this effect. Recent studies have reported that the epidermal growth factor (EGF) receptor shows an increase in expression in astrocytes after injury, and this receptor can promote their transformation into reactive astrocytes. Our results, along with previous works from others, show the colocalization of phosphor-EGF receptors with the astrocyte marker glial fibrillary acidic proteins in reactive astrocytes in the injured retina. In our in vitro studies, using primary astrocyte cultures of the optic nerve head of rats, showed that rapamycin significantly blocked EGF-induced mTOR signaling mainly through the PI3K/Akt pathway in primary astrocytes, but not through the MAPK/Erk pathway. Additionally, rapamycin dramatically inhibited the activation of mTOR signaling in our ratinal ischemia-reperfusion (I/R) injury model in vivo. Astrocyte activation was assessed by immunostaining retinal flat mounts or cross sections with antibody against GFAP, and we also used western blots to detect the expression of GFAP. Taken together, these results revealed that rapamycin decreases the activation of astrocytes after retinal ischemia-reperfusion injury. Furthermore, rapamycin can improve retinal RGC survival in rats during I/R, as detected by FluoroGold labeling. Our data reveals the neuroprotective effects of rapamycin in an experimental retina injury model, possibly through decreasing glialdependent intracellular signaling mechanisms for suppressing apoptosis of RGCs. Our study also presents an approach to targeting reactive astrocytes for the treatment of optic neurodegenerations.

Supplementary Figure 5 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i>nf1</i>-Deficient Astrocytes

Supplementary Figure 3 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i>nf1</i>-Deficient Astrocytes

Supplementary Figure Legends from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i>nf1</i>-Deficient Astrocytes

Supplementary Material and Methods from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i>nf1</i>-Deficient Astrocytes

Supplementary Figure 6 from Local and Systemic Immune Dysregulation Alters Glioma Growth in Hyperglycemic Mice

Supplementary Figure 1 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figure 3 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Supplementary Figures 1-4 from Glioblastoma Proto-oncogene <i>sec61γ</i> is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Supplementary Figure Legends from Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

Supplementary Figures from AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells

Mammalian Target of Rapamycin Inhibitor Abrogates Abnormal Osteoclastogenesis in Neurofibromatosis Type 1

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling.

Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas

Supplementary Figure 7 from Dysfunction of Nucleus Accumbens-1 Activates Cellular Senescence and Inhibits Tumor Cell Proliferation and Oncogenesis

Clustered, Regularly Interspaced Short Palindromic Repeats (Crispr)/cas9-Coupled Affinity Purification/Mass Spectrometry Analysis Revealed a Novel Role of Neurofibromin in Mtor Signaling.

Rapamycin Mediates Mtor Signaling in Reactive Astrocytes and Reduces Retinal Ganglion Cell Loss

Supplementary Figure 2 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figures and Tables from Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma Through JunD/Activator Protein-1 Transcriptional Activity

Supplementary Figure 5 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i&gt;nf1&lt;/i&gt;-Deficient Astrocytes

Supplementary Figure 3 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i&gt;nf1&lt;/i&gt;-Deficient Astrocytes

Supplementary Figure Legends from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i&gt;nf1&lt;/i&gt;-Deficient Astrocytes

Supplementary Material and Methods from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of &Lt;i&gt;nf1&lt;/i&gt;-Deficient Astrocytes